Fig. 6: CD36+ CAFs predict efficacy of HCC immunotherapy and targeting MIF synergizes with immunotherapy in HCC murine model. | Cell Discovery

Fig. 6: CD36+ CAFs predict efficacy of HCC immunotherapy and targeting MIF synergizes with immunotherapy in HCC murine model.

From: CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor

Fig. 6

a–c The HCC initiation and progression were evaluated in Cd36 and Mif conditional knockout (Acta2Cre) mice. d The proportion of MDSCs was downregulated in Cd36 and Mif conditional knockout (Acta2Cre) mice. e, f The prediction performance of CD36+ CAFs in HCC immunotherapy. g–k CD36 inhibitor SSO sythesizes PD-1 blockade in C57/BJ6 spontaneous HCC model. l, m The changes of Tregs, MDSC, IFN-γ+, GZMB+ CD8+ T cells in four different groups. Data shown as mean ± S.E.M., one-way ANOVA following multiple comparison test was used, ***P < 0.001, **P < 0.01, *P < 0.05, and ns not significant.

Back to article page